Role of ST2 in Acute Pancreatitis

Acute Pancreatitis Clinical Trial

Official title:

Study of ST2-IL-33 Pathway in Acute Pancreatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01315613
• Other study ID #: RO-ST2
• Status: Completed
• Phase: N/A
• First received: March 11, 2011
• Last updated: March 14, 2011
• Start date: January 2005
• Est. completion date: September 2008

Study information

• Verified date: September 2008
• Source: Erasme University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Acute pancreatitis is characterized by an inflammatory storm which regulatory pathways are not well known. The IL-1 cytokine family is activated early during acute pancreatitis and secretion of alarmins is speculated during pancreatic necrosis. IL-33 is a member of the IL-1 family, it can act as an alarmin and its receptor, ST2, is known to sequester MyD88 which might regulate the acute pancreatitis inflammatory storm. The aim of this study is to investigate ST2 pathway in human acute pancreatitis and in murine experimental models of acute pancreatitis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: September 2008
• Est. primary completion date: September 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Time to take blood sample less than 24h after the onset of symptoms of AP

• Two of the following: typical pain, amylase and lipase concentrations more than 3x the upper normal limit, compatible modifications on imaging techniques

Exclusion Criteria:

• Chronic pancreatitis

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Pancreatitis
• Pancreatitis

Locations

Country	Name	City	State
Belgium	Erasme Hospital	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Erasme University Hospital

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of soluble ST2 in serum	Concentration of soluble ST2 will be assessed in the serum of patient with an episode of acute pancreatitis, on the day of admission to the hospital as well as 24h, 48h, 7 days and 30 days later.	Within 30 days after onset of acute pancreatitis	No